Blade (BLDE) Q2 Revenue Jumps 10%

Blade Air Mobility reported Q2 2025 GAAP revenue of $70.8 million, surpassing expectations by 10.5%, with adjusted EBITDA more than tripling to $3.2 million despite negative free cash flow. The company announced a significant strategic pivot, divesting its Passenger division to Joby Aviation for up to $125 million, to exclusively focus on its higher-growth Medical segment, which saw revenue increase 17.6% to $45.1 million. This move transforms Blade into a dedicated medical air mobility provider, soon rebranding as Strata Critical Medical, aiming for annualized cost reductions and a pro forma liquidity exceeding $200 million post-transaction.

Analysis

Blade Air Mobility's Q2 2025 results signal a pivotal strategic transformation, underscored by strong operational performance in its core business. The company reported GAAP revenue of $70.8 million, a 10.5% beat against estimates, and more than tripled its adjusted EBITDA year-over-year to $3.2 million. The most significant development is the divestiture of its Passenger division to Joby Aviation for up to $125 million, a move that will reshape Blade into a pure-play medical air mobility company named Strata. This focus is supported by the Medical segment's robust 17.6% revenue growth to $45.1 million. However, this growth was accompanied by a temporary margin contraction, with Medical Flight Margin declining to 22.0% from 23.6% due to higher maintenance costs, which management expects to normalize. A notable concern is the negative free cash flow of $(5.7) million, a significant swing from a positive $6.2 million in the prior year, attributed to working capital demands. The sale of the Passenger unit is projected to be neutral to adjusted EBITDA and free cash flow annually, aided by approximately $7 million in cost reductions, and will boost pro forma liquidity to over $200 million, providing substantial capital for growth and technology integration, including the planned adoption of eVTOL aircraft through its partnership with Joby.

Key Decisions for Investors

• Investors should re-evaluate their thesis for Blade, as the company is transitioning from a diversified air mobility operator to a focused, pure-play medical logistics provider, which alters both the growth profile and risk concentration.
• The divestiture provides a significant cash infusion, so it is critical to monitor management's capital allocation strategy for accelerating growth in the core Medical segment and the timeline for realizing projected cost savings.
• While Medical segment revenue growth is strong, closely track the recovery of Medical Flight Margins from the current 22.0% and the return to positive free cash flow in coming quarters to validate the long-term profitability of the new standalone entity.
• Consider holding positions until the company provides updated post-divestiture financial guidance, as this will offer crucial clarity on the standalone earnings power and valuation of the rebranded 'Strata' business.